Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms

Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms: a Patient-derived Tumoroids Prospective Collection From Systemic Treatment Naive Tumors

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05038358

Acronym

CRC-ORGA2

Enrollment

Registered

2021-09-09

Start date

2022-12-12

Completion date

2030-12-31

Last updated

2026-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Tumor, Primary Tumor

Keywords

Organoid collection from fresh human primary colonic tumor tissue

Brief summary

Colorectal cancer is the third most common cancer worldwide and its progression-free survival is still low, around 10 months. Thirthy to 50% of patients do not respond to chemotherapy upon initiation of treatment, suggesting that early development of chemoresistance mechanisms remains a major challenge. In order to better characterize these mechanisms, the aim is to develop a model of tumoroids derived from patients with a colorectal tumors prior to any systemic anti cancer treatment. This project will both allow us to study the role of the immunological microenvironment in chemoresistance and identify new predictive markers of tumor response. It will then serve to develop innovative personalized medicine strategies by targeting the newly identified mechanisms. This study should in fine help to improve the cancer patient's care.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male and female over 18 years old. * Managed at the CHUGA for a colorectal adenocarcinoma * With an indication for immediate surgical resection as part of the care. * Patient naive from neo-adjuvant chemotherapy * Patient did not object to the CRC-ORGA-2 study

Exclusion criteria

* Patients protected by law (pregnant or breastfeeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalized under duress). * Patients with positive HIV, HBV, HCV serology.

Design outcomes

Primary

Measure	Time frame
Percentage of viable organoids for 60 days of culture maintenance.	60 days of culture maintenance.

Countries

France

Contacts

CONTACTGAEL ROTH, MD, PHD

GRoth@chu-grenoble.fr04 76 76 51 68

CONTACTARNAUD MILLET, MD, PHD

arnaud.millet@inserm.fr

PRINCIPAL_INVESTIGATORGAEL ROTH, MD, PHD

university hospital of Grenoble alpes

Outcome results